midostaurin-sensitive FLT3 mutants [plasma membrane]

Stable Identifier
Set [DefinedSet]
Homo sapiens
Locations in the PathwayBrowser
Literature References
PubMed ID Title Journal Year
20520641 Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib

Menzel, H, Sigl, M, Rummelt, C, Duyster, J, von Bubnoff, N, Peschel, C

Leukemia 2010
28077790 FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors

Levis, M, Nguyen, B, Williams, AB, Small, D, Brown, P, Li, L, Young, DJ, Ma, H

Oncotarget 2017
16868253 The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases

Gilkes, AF, Mills, KI, Austin, SJ, Burnett, AK, Knapper, S, Walsh, V

Blood 2006
18068628 Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles

Griffin, JD, Golub, TR, Gilliland, DG, Heinrich, MC, Ebert, BL, Stone, RM, Jiang, J, Schittenhelm, MM, Berger, R, Lee, BH, Deininger, MW, Teckie, S, Döhner, K, Loriaux, M, Fröhling, S, Bernard, OA, Scholl, C, Boggon, TJ, Levine, RL, Döhner, H, Druker, BJ

Cancer Cell 2007
17827387 Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin

Barry, EV, Gilliland, DG, Clark, JJ, Cools, J, Roesel, J

Blood 2007
23392356 The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib

Yu, C, Albers, C, Verbeek, M, Duyster, J, Leischner, H, Illert, AL, von Bubnoff, N, Peschel, C

Leukemia 2013
27132990 Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation

Huang, A, Liu, K, Wen, S, Huang, P, Liu, D, Hu, Y, Garcia-Manero, G, Ju, HQ, Zhan, G

Cancer Lett. 2016
22858906 Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors

Nguyen, B, Brown, P, Li, L, Levis, M, Williams, AB, Leahy, D, Small, D

Leukemia 2013
23969938 Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia

Mullighan, CG, Baker, SD, Rubnitz, JE, Zimmerman, EI, Orwick, S, Inaba, H, Neale, GA, Zatechka, DS, Buaboonnam, J, Enemark, EJ, Shurtleff, S, Wang, YD, Olsen, SR

Clin. Cancer Res. 2013
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!